Spread the love“`html Imagine a future where the relentless march of time slows down, where the creaks and groans of aging ...
Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.
AstraZeneca pays $40 million upfront to put insitro's AI platform to work on metabolic dysfunction-associated steatohepatitis ...
India’s Drug Market Grows 17.1% in September 2026 as Global Pharma Companies Accelerate Innovation, Capacity Expansion and ...
AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.
Indian scientists and biopharmaceutical firms are using artificial intelligence to identify promising drug candidates faster ...
By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billion
AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with insitro to use artificial intelligence to identify new drug targets and develop potential treatments ...
Biotechnology firm INmune Bio Inc. (NASDAQ: INMB) and photonic quantum developer Quantum Computing Inc. (NASDAQ: QUBT) have ...
Curitiba-based biotechnology company advances synthesized compounds into in vitro testing in Brazilian laboratories.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results